VEGFA and cardiac arrhythmia: The use of vascular endothelial growth factor inhibitors (VEGFI) and TKIs in oncological therapy may lead to cardiotoxicity expressed by arterial hypertension, left ventricular systolic dysfunction, heart failure and arterial and venous thromboembolism, as well as prolongation of the QTc interval and arrhythmia [26].